<DOC>
	<DOCNO>NCT01566240</DOCNO>
	<brief_summary>Chemoradiation standard treatment advanced cervical cancer decade , one third woman still die failure control systemic disease . In recent multicentre phase II trial 46 woman investigator find , 68 % woman tumours responded weekly induction chemotherapy prior chemoradiation . The induction chemotherapy acceptable toxicity compromise standard chemoradiation treatment . In addition , overall survival progression free survival 3 year 66 % ( 95 % CI 4779 ) . These result , together acceptable toxicity , provide justification evaluate induction chemotherapy prior chemoradiation randomise phase III trial . The investigator aim investigate randomise trial whether additional induction chemotherapy give weekly schedule immediately standard chemoradiation lead improvement overall survival . The investigator plan recruit 770 woman locally advanced cervical cancer eligible standard chemoradiation , randomise weekly carboplatin paclitaxel chemotherapy 6 week follow chemoradiation chemoradiation alone . The trial recruit 4 year 5 year follow period .</brief_summary>
	<brief_title>Induction Chemotherapy Plus Chemoradiation First Line Treatment Locally Advanced Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically confirm FIGO stage Ib2IVa squamous , adeno adenosquamous carcinoma cervix ( except FIGO IIIA ) . Patients histologically confirm FIGO stage IB1 positive lymph node also eligible Deemed suitable fit radical chemoradiation Medically fit receive carboplatin paclitaxel ECOG performance status 0 1 No evidence active TB Aged 18 Adequate renal function , define GFR ≥ 60 ml/min calculate use Wright equation ( ≥ 50 ml/min radioisotope GFR assessment ) Adequate liver function , define ALT AST &lt; 2.5 ULN bilirubin &lt; 1.25 ULN Adequate bone marrow function define ANC ≥1.5 x 109/L , platelet ≥ 100 x 109/L Using adequate contraception precaution relevant A documented negative HIV test ( patient recruit high risk country move within past 10 year high risk country ) A documented negative pregnancy test ( applicable ) Capable provide write witnessed informed consent Patients positive ( pelvic/paraaortic/both ) node ( either histologically/PET positive ≥15 mm CT/MRI ) level aortic bifurcation may include study provide none exclusion criterion apply . Previous pelvic malignancy ( regardless interval since diagnosis ) Previous malignancy affect pelvis ( except basal cell carcinoma skin ) disease free interval le 10 year Positive lymph node ( image histological ) aortic bifurcation* Hydronephrosis undergone ureteric stenting nephrostomy except affected kidney nonfunctioning Evidence distant metastasis i.e . nonnodal metastasis beyond pelvis Previous pelvic radiotherapy Prior diagnosis Crohn 's disease Ulcerative colitis Uncontrolled cardiac disease ( defined cardiac function would preclude hydration cisplatin administration contraindication paclitaxel ) Pregnant lactate * i.e . PET size , CT/MRI ≥ 15mm</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>cervical cancer</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Chemoradiation</keyword>
	<keyword>Brachytherapy</keyword>
	<keyword>Stage IB2 Cervical Cancer</keyword>
	<keyword>Stage IIA Cervical Cancer</keyword>
	<keyword>Stage IIB Cervical Cancer</keyword>
	<keyword>Stage IIIB Cervical Cancer</keyword>
	<keyword>Stage IVA Cervical Cancer</keyword>
</DOC>